Advances in lipid testing and management in patients with diabetes mellitus

Endocrine Practice

Volumn 15, Issue 6, 2009, Pages 641-652

  Vasudevan, Madhuri M ^a   Ballantyne, Christie M ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN B; ATORVASTATIN; BILE ACID SEQUESTRANT; COLESEVELAM; EZETIMIBE; EZETIMIBE PLUS SIMVASTATIN; FENOFIBRATE; FIBRIC ACID DERIVATIVE; GEMFIBROZIL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ICOSAPENTAENOIC ACID; LIPID; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NICOTINIC ACID; NICOTINIC ACID PLUS SIMVASTATIN; OMEGA 3 FATTY ACID; ORAL ANTIDIABETIC AGENT; PLACEBO; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN; ANTILIPEMIC AGENT;

ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL PRACTICE; CLINICAL TRIAL; DIABETES MELLITUS; DIET; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE PREDISPOSITION; DRUG MEGADOSE; DYSLIPIDEMIA; EXERCISE; FLUSHING; GASTROINTESTINAL SYMPTOM; HUMAN; HYPERTRIGLYCERIDEMIA; INCIDENCE; ISCHEMIC HEART DISEASE; LIFESTYLE MODIFICATION; LIPID ANALYSIS; LOW DRUG DOSE; MACROVASCULAR COMPLICATION; MICROANGIOPATHY; MONITORING; MONOTHERAPY; MORBIDITY; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; PARTICLE SIZE; PATHOPHYSIOLOGY; PATIENT COMPLIANCE; PHENOTYPE; PREVALENCE; REVIEW; RISK ASSESSMENT; RISK REDUCTION; SIDE EFFECT; THROMBOSIS; TREATMENT RESPONSE; UNITED STATES; VASCULAR DISEASE; WEIGHT REDUCTION; RISK FACTOR;

ANTILIPEMIC AGENTS; CLINICAL TRIALS AS TOPIC; DIABETES COMPLICATIONS; DYSLIPIDEMIAS; HUMANS; RISK FACTORS;

EID: 75549091053     PISSN: 1530891X     EISSN: None     Source Type: Journal    
DOI: 10.4158/EP09190.RA     Document Type: Review

References (90)

1. World Health Organization (WHO). Diabetes programme: country and regional data; facts and figures. http://www.who.int/diabetes/facts/world- figures/en/index.html. Accessed for verification July 13, 2009.
2. Centers for Disease Control and Prevention (CDC). Diabetes data & trends: number (in millions) of civilian/noninstitutionalized persons with diagnosed diabetes, United States, 1980-2006. http://www.cdc.gov/diabetes/ Statistics/prev/national/figpersons.htm. Accessed for verification July 13, 2009.
3. American Diabetes Association. Total prevalence of diabetes & pre-diabetes. http://www.diabetes.org/diabetes-statistics/prevalence.jsp. Accessed for verification July 13, 2009.
4. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001;285:2486-2497.
5. Grundy SM, Cleeman JI, Merz CN, et al (National Heart, Lung, and Blood Institute; American College of Cardiology Foundation; American Heart Institute). Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines [published correction appears in Circulation. 2004;110:763]. Circulation. 2004;110:227-239.
6. Brunzell JD, Davidson M, Furberg CD, et al. Lipoprotein management in patients with cardiometabolic risk: consensus conference report from the American Diabetes Association and the American College of Cardiology Foundation. J Am Coll Cardiol. 2008;51:1512-1524.
7. American Diabetes Association. Standards of medical care in diabetes - 2009. Diabetes Care. 2009;32(suppl 1):S13-S61.
8. Collins R, Armitage J, Parish S, et al (Heart Protection Study Collaborative Group). MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet. 2003;361:2005-2016.
9. Mooradian AD. Dyslipidemia in type 2 diabetes mellitus. Nat Clin Pract Endocrinol Metab. 2009;5:150-159.
10. Meigs JB, Nathan DM, Wilson PW, Cupples LA, Singer DE. Metabolic risk factors worsen continuously across the spectrum of nondiabetic glucose tolerance: the Framingham Offspring Study. Ann Intern Med. 1998;128:524-533.
11. Howard BV, Mayer-Davis EJ, Goff D, et al. Relationships between insulin resistance and lipoproteins in nondiabetic African Americans, Hispanics, and non-Hispanic whites: the Insulin Resistance Atherosclerosis Study. Metabolism. 1998;47:1174-1179.
12. Haffner SM, Miettinen H, Stern MP. Relatively more atherogenic coronary heart disease risk factors in prediabetic women than in prediabetic men. Diabetologia. 1997;40:711-717.
13. Bays H, Ballantyne C. Adiposopathy: why do adiposity and obesity cause metabolic disease? Future Lipidol. 2006;1:389-420.
14. Montecucco F, Steffens S, Mach F. Insulin resistance: a proinflammatory state mediated by lipid-induced signaling dysfunction and involved in atherosclerotic plaque instability. Mediators Inflamm. 2008;2008:767623.
15. Taskinen MR. Diabetic dyslipidaemia: from basic research to clinical practice. Diabetologia. 2003;46:733-749.
16. Krauss RM, Siri PW. Dyslipidemia in type 2 diabetes. Med Clin North Am. 2004;88:897-909, x.
17. Del Pilar Solano M, Goldberg RB. Management of diabetic dyslipidemia. Endocrinol Metab Clin North Am. 2005;34:1-25, v.
18. Chahil TJ, Ginsberg HN. Diabetic dyslipidemia. Endocrinol Metab Clin North Am. 2006;35:491-510, vii-viii.
19. Mora S, Rifai N, Buring JE, Ridker PM. Comparison of LDL cholesterol concentrations by Friedewald calculation and direct measurement in relation to cardiovascular events in 27,331 women. Clin Chem. 2009;55:888-894.
20. Cui Y, Blumenthal RS, Flaws JA, et al. Non-high-density lipoprotein cholesterol level as a predictor of cardiovascular disease mortality. Arch Intern Med. 2001;161:1413-1419.
21. Ridker PM, Rifai N, Cook NR, Bradwin G, Buring JE. Non-HDL cholesterol, apolipoproteins A-I and B100, standard lipid measures, lipid ratios, and CRP as risk factors for cardiovascular disease in women. JAMA. 2005;294:326-333.
22. Bittner V, Hardison R, Kelsey SF, et al. Non-high-density lipoprotein cholesterol levels predict five-year outcome in the Bypass Angioplasty Revascularization Investigation (BARI). Circulation. 2002;106:2537-2542.
23. Walldius G, Jungner I, Holme I, Aastveit AH, Kolar W, Steiner E. High apolipoprotein B, low apolipoprotein A-I, and improvement in the prediction of fatal myocardial infarction (AMORIS study): a prospective study. Lancet. 2001;358:2026-2033.
24. Yusuf S, Hawken S, Ounpuu S, et al (INTERHEART Study Investigators). Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet. 2004;364:937-952.
25. Sattar N, Williams K, Sniderman AD, D'Agostino R Jr, Haffner SM. Comparison of the associations of apolipoprotein B and non-high-density lipoprotein cholesterol with other cardiovascular risk factors in patients with the metabolic syndrome in the Insulin Resistance Atherosclerosis Study. Circulation. 2004;110:2687-2693.
26. Kathiresan S, Otvos JD, Sullivan LM, et al. Increased small low-density lipoprotein particle number: a prominent feature of the metabolic syndrome in the Framingham Heart Study. Circulation. 2006;113:20-29.
27. Pyörälä K, Pedersen TR, Kjekshus J, Faergman O, Olsson AG, Thorgeirsson G. Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease: a subgroup analysis of the Scandinavian Simvastatin Survival Study (4S) [published correction appears in Diabetes Care. 1997;20:1048]. Diabetes Care. 1997;20:614-620.
28. Long-Term Intervention With Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med. 1998;339:1349-1357.
29. Gotto AM Jr, Whitney E, Stein EA, et al. Relation between baseline and on-treatment lipid parameters and first acute major coronary events in the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS). Circulation. 2000;101:477-484.
30. Kastelein JJ, van der Steeg WA, Holme I, et al (TNT Study Group; IDEAL Study group). Lipids, apolipoproteins, and their ratios in relation to cardiovascular events with statin treatment. Circulation. 2008;117:3002-3009.
31. Ballantyne CM, Raichlen JS, Cain VA. Statin therapy alters the relationship between apolipoprotein B and low-density lipoprotein cholesterol and non-high-density lipoprotein cholesterol targets in high-risk patients: the MERCURY II (Measuring Effective Reductions in Cholesterol Using Rosuvastatin) trial. J Am Coll Cardiol. 2008;52:626-632.
32. Grundy SM. Low-density lipoprotein, non-high-density lipoprotein, and apolipoprotein B as targets of lipid-lowering therapy. Circulation. 2002;106:2526-2529.
33. Ballantyne CM, Andrews TC, Hsia JA, Kramer JH, Shear C (ACCESS Study Group, Atorvastatin Comparative Cholesterol Efficacy and Safety Study). Correlation of non-high-density lipoprotein cholesterol with apolipoprotein B: effect of 5 hydroxymethylglutaryl coenzyme A reductase inhibitors on non-high-density lipoprotein cholesterol levels. Am J Cardiol. 2001;88:265-269.
34. Austin MA, Breslow JL, Hennekens CH, Buring JE, Willett WC, Krauss RM. Low-density lipoprotein subclass patterns and risk of myocardial infarction. JAMA. 1988;260:1917-1921.
35. Austin MA, King MC, Vranizan KM, Krauss RM. Atherogenic lipoprotein phenotype: a proposed genetic marker for coronary heart disease risk. Circulation. 1990;82:495-506.
36. St-Pierre AC, Ruel IL, Cantin B, et al. Comparison of various electrophoretic characteristics of LDL particles and their relationship to the risk of ischemic heart disease. Circulation. 2001;104:2295-2299.
37. Mora S, Szklo M, Otvos JD, et al. LDL particle subclasses, LDL particle size, and carotid atherosclerosis in the Multi-Ethnic Study of Atherosclerosis (MESA). Atherosclerosis. 2007;192:211-217.
38. Campos H, Moye LA, Glasser SP, Stampfer MJ, Sacks FM. Low-density lipoprotein size, pravastatin treatment, and coronary events. JAMA. 2001;286:1468-1474.
39. O'Leary DH, Polak JF. Intima-media thickness: a tool for atherosclerosis imaging and event prediction. Am J Cardiol. 2002;90:18L-21L.
40. Lyons TJ, Jenkins AJ, Zheng D, et al (DCCT/EDIC Research Group). Nuclear magnetic resonance-determined lipoprotein subclass profile in the DCCT/EDIC cohort: associations with carotid intima-media thickness. Diabet Med. 2006;23:955-966.
41. Mora S, Otvos JD, Rifai N, Rosenson RS, Buring JE, Ridker PM. Lipoprotein particle profiles by nuclear magnetic resonance compared with standard lipids and apolipoproteins in predicting incident cardiovascular disease in women. Circulation. 2009;119:931-939.
42. Howard BV, Roman MJ, Devereux RB, et al. Effect of lower targets for blood pressure and LDL cholesterol on atherosclerosis in diabetes: the SANDS randomized trial. JAMA. 2008;299:1678-1689.
43. Davidson MH, Maki KC, Pearson TA, et al. Results of the National Cholesterol Education (NCEP) Program Evaluation ProjecT Utilizing Novel E-Technology (NEPTUNE) II survey and implications for treatment under the recent NCEP Writing Group recommendations. Am J Cardiol. 2005;96:556-563.
44. National Institutes of Health, National Heart, Lung, and Blood Institute, North American Association for the Study of Obesity. The practical guide: identification, evaluation, and treatment of overweight and obesity in adults. Bethesda, MD: National Institutes of Health, October 2000. NIH publication 00-4084. http://www.nhlbi.nih.gov/guidelines/obesity/prctgd-c. pdf. Accessed for verification July 13, 2009.
45. Case CC, Jones PH, Nelson k, O'Brian Smith E, Ballantyne CM. Impact of weight loss on the metabolic syndrome. Diabetes Obes Metab. 2002;4:407-414.
46. Pi-Sunyer X, Blackburn G, Brancati FL, et al (Look AHEAD Research Group). Reduction in weight and cardiovascular disease risk factors in individuals with type 2 diabetes: one-year results of the Look AHEAD trial. Diabetes Care. 2007;30:1374-1383.
47. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III): final report. Circulation. 2002;106:3143-3421.
48. Mensink RP, Zock PL, Kester AD, Katan MB. Effects of dietary fatty acids and carbohydrates on the ratio of serum total to HDL cholesterol and on serum lipids and apolipoproteins: a meta-analysis of 60 controlled trials. Am J Clin Nutr. 2003;77:1146-1155.
49. Dansinger ML, Schaefer EJ. Low-carbohydrate or lowfat diets for the metabolic syndrome? Curr Diab Rep. 2006;6:55-63.
50. LaMonte MJ, Blair SN, Church TS. Physical activity and diabetes prevention. J Appl Physiol. 2005;99:1205-1213.
51. Harris WS. n-3 fatty acids and serum lipoproteins: human studies. Am J Clin Nutr. 1997;65(5 suppl):1645S-1654S.
52. Harris WS, Ginsberg HN, Arunakul N, et al. Safety and efficacy of Omacor in severe hypertriglyceridemia. J Cardiovasc Risk. 1997;4:385-391.
53. Sasaki J, Iwashita M, Kono S. Statins: beneficial or adverse for glucose metabolism. J Atheroscler Thromb. 2006;13:123-129.
54. Coleman CI, Reinhart K, Kluger J, White CM. The effect of statins on the development of new-onset type 2 diabetes: a meta-analysis of randomized controlled trials. Curr Med Res Opin. 2008;24:1359-1362.
55. Colhoun HM, Betteridge DJ, Durrington PN, et al (CARDS Investigators). Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet. 2004;364:685-696.
56. Soedamah-Muthu SS, Colhoun HM, Thomason MJ, et al (CARDS Investigators). The effect of atorvastatin on serum lipids, lipoproteins and NMR spectroscopy defined lipoprotein subclasses in type 2 diabetic patients with ischaemic heart disease. Atherosclerosis. 2003;167:243-255.
57. Wanner C, Krane V, März W, et al (German Diabetes and Dialysis Study Investigators). Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis [published correction appears in N Engl J Med. 2005;353:1640]. N Engl J Med. 2005;353:238-248.
58. Knopp RH, d'Emden M, Smilde JG, Pocock SJ. Efficacy and safety of atorvastatin in the prevention of cardiovascular end points in subjects with type 2 diabetes: the Atorvastatin Study for Prevention of Coronary Heart Disease Endpoints in Non-Insulin-Dependent Diabetes Mellitus (ASPEN). Diabetes Care. 2006;29:1478-1485.
59. Kearney PM, Blackwell L, Collins R, et al (Cholesterol Treatment Trialists' [CTT] Collaborators). Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet. 2008;371:117-125.
60. Ahmed S, Cannon CP, Murphy SA, Braunwald E. Acute coronary syndromes and diabetes: is intensive lipid lowering beneficial? Results of the PROVE IT-TIMI 22 trial. Eur Heart J. 2006;27:2323-2329.
61. Shepherd J, Barter P, Carmena R, et al. Effect of lowering LDL cholesterol substantially below currently recommended levels in patients with coronary heart disease and diabetes: the Treating to New Targets (TNT) study. Diabetes Care. 2006;29:1220-1226.
62. Ridker PM, Danielson E, Fonseca FA, et al (JUPITER Study Group). Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359:2195-2207.
63. Ridker PM. The JUPITER trial: results, controversies, and implications for prevention. Circ Cardiovasc Qual Outcomes. 2009;2:279-285.
64. Superko HR, McGovern ME, Raul E, Garrett B. Differential effect of two nicotinic acid preparations on low-density lipoprotein subclass distribution in patients classified as low-density lipoprotein pattern A, B, or I. Am J Cardiol. 2004;94:588-594.
65. Carlson LA, Hamsten A, Asplund A. Pronounced lowering of serum levels of lipoprotein Lp(a) in hyperlipidaemic subjects treated with nicotinic acid. J Intern Med. 1989;226:271-276.
66. Guyton JR, Bays HE. Safety considerations with niacin therapy. Am J Cardiol. 2007;99:22C-31C.
67. Elam MB, Hunninghake DB, Davis KB, et al (Arterial Disease Multiple Intervention Trial [ADMIT] Investigators). Effect of niacin on lipid and lipoprotein levels and glycemic control in patients with diabetes and peripheral arterial disease: the ADMIT study; a randomized trial. JAMA. 2000;284:1263-1270.
68. Grundy SM, Vega GL, McGovern ME, et al (Diabetes Multicenter Research Group). Efficacy, safety, and tolerability of once-daily niacin for the treatment of dyslipidemia associated with type 2 diabetes: results of the Assessment of Diabetes Control and Evaluation of the Efficacy of Niaspan Trial. Arch Intern Med. 2002;162:1568-1576.
69. Coronary Drug Project Research Group. Clofibrate and niacin in coronary heart disease. JAMA. 1975;231:360-381.
70. Canner PL, Berge KG, Wenger NK, et al. Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin. J Am Coll Cardiol. 1986;8:1245-1255.
71. Canner PL, Furberg CD, Terrin ML, McGovern ME. Benefits of niacin by glycemic status in patients with healed myocardial infarction (from the Coronary Drug Project). Am J Cardiol. 2005;95:254-257.
72. Staels B, Dallongeville J, Auwerx J, Schoonjans K, Leitersdork E, Fruchart JC. Mechanism of action of fibrates on lipid and lipoprotein metabolism. Circulation. 1998;98:2088-2093.
73. Muhlestein JB, May HT, Jensen JR, et al. The reduction of inflammatory biomarkers by statin, fibrate, and combination therapy among diabetic patients with mixed dyslipidemia: the DIACOR (Diabetes and Combined Lipid Therapy Regimen) study. J Am Coll Cardiol. 2006;48:396-401.
74. Manninen V, Tenkanen L, Koskinen P, et al. Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study: implications for treatment. Circulation. 1992;85:37-45.
75. Rubins HB, Robins SJ, Collins D, et al. Diabetes, plasma insulin, and cardiovascular disease: subgroup analysis from the Department of Veterans Affairs High-Density Lipoprotein Intervention Trial (VA-HIT). Arch Intern Med. 2002;162:2597-2604.
76. Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: the Diabetes Atherosclerosis Intervention Study, a randomised study. Lancet. 2001;357:905-910.
77. Keech A, Simes RJ, Barter P, et al (FIELD Study Investigators). Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial [published corrections appear in Lancet. 2006;368:1415 and Lancet. 2006;368:1420]. Lancet. 2005;366:1849-1861.
78. Scott R, O'Brien R, Fulcher G, et al (Fenofibrate Intervention and Event Lowering in Diabetes [FIELD] Study Investigators). Effects of fenofibrate treatment on cardiovascular disease risk in 9,795 individuals with type 2 diabetes and various components of the metabolic syndrome: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. Diabetes Care. 2009;32:493-498.
79. Chan DC, Watts GF, Barrett PH, Bellin LJ, Redgrave TG, Mori TA. Regulatory effects of HMG CoA reductase inhibitor and fish oils on apolipoprotein B-100 kinetics in insulin-resistant obese male subjects with dyslipidemia. Diabetes. 2002;51:2377-2386.
80. Davidson MH, Stein EA, Bays HE, et al (COMBination of prescription Omega-3 with Simvastatin [COMBOS] Investigators). Efficacy and tolerability of adding prescription omega-3 fatty acids 4 g/d to simvastatin 40 mg/d in hypertriglyceridemic patients: an 8-week, randomized, double-blind, placebo-controlled study. Clin Ther. 2007;29:1354-1367.
81. Marchioli R, Marfisi RM, Borrelli G, et al. Efficacy of n-3 polyunsaturated fatty acids according to clinical characteristics of patients with recent myocardial infarction: insights from the GISSI-Prevenzione trial. J Cardiovasc Med (Hagerstown). 2007;8(suppl 1):S34-S37.
82. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardico. Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial [published corrections appear in Lancet. 2001;357:642 and Lancet. 2007;369:106]. Lancet. 1999;354:447-455.
83. Saito Y, Yokoyama M, Origasa H, et al (JELIS Investigators, Japan). Effects of EPA on coronary artery disease in hypercholesterolemic patients with multiple risk factors: sub-analysis of primary prevention cases from the Japan EPA Lipid Intervention Study (JELIS). Atherosclerosis. 2008;200:135-140.
84. Zieve FJ, Kalin MF, Schwartz SL, Jones MR, Bailey WL. Results of the Glucose-Lowering Effect of WelChol Study (GLOWS): a randomized, double-blind, placebo-controlled pilot study evaluating the effect of colesevelam hydrochloride on glycemic control in subjects with type 2 diabetes. Clin Ther. 2007;29:74-83.
85. Nambi V, Ballantyne CM. Combination therapy with statins and omega-3 fatty acids. Am J Cardiol. 2006;98:34i-38i.
86. Xydakis AM, Ballantyne CM. Combination therapy for combined dyslipidemia. Am J Cardiol. 2002;90:21K-29K.
87. Goldberg RB, Guyton JR, Mazzone T, et al. Ezetimibe/simvastatin vs atorvastatin in patients with type 2 diabetes mellitus and hypercholesterolemia: the VYTAL study [published correction appears in Mayo Clin Proc. 2007;82:387]. Mayo Clin Proc. 2006;81:1579-1588.
88. Ballantyne CM, Davidson MH, McKenney J, Keller LH, Bajorunas DR, Karas RH. Comparison of the safety and efficacy of a combination tablet of niacin extended release and simvastatin vs simvastatin monotherapy in patients with increased non-HDL cholesterol (from the SEACOAST I study). Am J Cardiol. 2008;101:1428-1436.
89. Fleg JL, Mete M, Howard BV, et al. Effect of statins alone versus statins plus ezetimibe on carotid atherosclerosis in type 2 diabetes: the SANDS (Stop Atherosclerosis in Native Diabetics Study) trial. J Am Coll Cardiol. 2008;52:2198-2205.
90. Ginsberg HN, Bonds DE, Lovato LC, et al (ACCORD Study Group). Evolution of the lipid trial protocol of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Am J Cardiol. 2007;99:56i-67i.